Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CART123 cells |
| Synonyms | |
| Therapy Description |
CART123 cells are T-cells engineered to express a chimeric antigenic receptor (CAR) targeting CD123 and linked to 4-1BB and CD3zeta signaling domains, which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 24596416). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CART123 cells | CART123 cells are T-cells engineered to express a chimeric antigenic receptor (CAR) targeting CD123 and linked to 4-1BB and CD3zeta signaling domains, which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 24596416). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06765876 | Phase I | CART123 cells | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: a Dose Escalation Phase I Trial (UHKT-CAR123-01) | Recruiting | CZE | 0 |
| NCT04678336 | Phase I | CART123 cells Cyclophosphamide + Fludarabine | CD123 Redirected T Cells for AML in Pediatric Subjects | Terminated | USA | 0 |